Zhangjiagang CIMC Sanctum Cryogenic Equipment, a subsidiary of CIMIC Enric Holdings, has started research and development (R&D) of liquid nitrogen biological containers to meet the needs of the biomedical industry, including the long-term cryogenic storage of Covid-19 vaccines.

Alongside the Covid-19 vaccine, the Chinese company said its development will also help the storage of stem cells, plasma, semen, embryos and various tissues and organs.

The liquid nitrogen biological container will be designed on the GN14174 large-caliber liquid nitrogen container standard. Upon successful development, the equipment will adopt advanced technologies such as high vacuum multilayer insulation, electronic temperature control, and liquid nitrogen dispersion to make the intelligent cooling and constant temperature process uniform and stable.

It is expected that the product will provide immersion storage and vapor phase storage in two ways, providing users with a fully automatic, safe and reliable cryogenic liquid nitrogen storage system.

Developed specifically for cryogenic storage of biological samples, the equipment body will be made of stainless steel with its own moving and braking device. It will support full-opening and has large opening for sample storage. The equipment is designed with lowest-possible liquid nitrogen consumption for large sample storage capacity and better cost savings per unit sample.

Mr. Yang Xiaohu, General Manager and Executive Director of CIMC Enric, commented, “The mass production of domestic and foreign vaccines is just around the corner, but the cold chain storage and transportation of vaccines is still one of the challenges that countries need to overcome together.”

“As the industry leader, the company has rich experience and advanced technology in the field of cryogenic storage, transportation and smart temperature control. The company also sees the demand for biomedical cryogenic storage equipment derived from the epidemic and has begun to increase related R&D investment with the vision to establish a more complete vaccine cold chain storage and transportation system.” 

Mr. Xu Zhiquan, General Manager and Director of CIMC Sanctum added, “As CIMC Enric’s backbone subsidiary specialised in cryogenic equipment manufacturing, CIMC Sanctum has powerful R&D institutes including a National Post-Doctoral Scientific Research Workstation, the Technology Centre of Jiangsu Province, and the Cryogenic Storage and Transport Equipment Engineering Technology Research Centre of Jiangsu Province.

“Cryogenic vaccine storage containers and the Company’s current cryogenic storage and transportation equipment share similar technologies. CIMC Sanctum has the ability and strength to develop cryogenic storage equipment for biomedical products. Biomedical cryogenic storage equipment is the infrastructure of the medical testing centres. The outbreak of Covid-19 has revealed the huge gap in related equipment.”

“The Company’s new deployment is to meet with the urgent needs of China and the world to transform the testing capabilities and cryogenic storage of the new Covid-19 vaccine, to explore the huge potential of biomedical cryogenic storage industry and generating more diversified income.”